Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Chemotherapy and Radio-Chemotherapy of Locally Advanced Esophageal Cancer Surgical resection alone of locally advanced esophageal carcinoma leads to long-term survival in only about 30% of cases. The multimodal strategy for locally advanced tumors, especially neoadjuvant radiochemotherapy and chemotherapy, has significantly improved the long-term prognosis. Multimodal therapy concepts have been developed which improve overall survival. Therapy planning must be performed pretherapeutically in an interdisciplinary tumor board, preferably at a high-volume center. For squamous cell carcinomas, neoadjuvant radio/chemotherapy followed by resection or definitive radio/chemotherapy are currently the therapies of choice. For adenocarcinomas, neoadjuvant radio/chemotherapy followed by resection or perioperative chemotherapy are considered equivalent therapeutic standards. After neoadjuvant radiochemotherapy, adjuvant immunotherapy is currently recommended in case of only incomplete histopathological response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/0040-5930/a001347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Constructing Aggregation-Induced Emission Luminogens With Significantly Improved Performance Through Local Chemical Modification From Thiophene to Thiophene Sulfone.
Luminescence
September 2025
Beijing Key Laboratory of Energy Conversion and Storage Materials, Beijing, China.
A novel aggregation-induced emission (AIE) system with superior performance was successfully developed through local chemical modification from thiophene to thiophene sulfone. This approach, leveraging easily accessible tetraphenylthiophene precursors, dramatically enhances the photophysical properties in a simple oxidation step. Notably, the representative 2,3,4,5-tetraphenylthiophene sulfone (3c) demonstrates remarkable solid-state emission characteristics with a fluorescence quantum yield of 72% and an AIE factor of 240, substantially outperforming its thiophene analog.
View Article and Find Full Text PDFResearch progress on bioactive peptides in the treatment of oral diseases.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Maxillofacial Surgery, Xiangya Hospital of Stomatology, Central South University, Changsha 410013, China.
Peptide-based drugs possess several advantages, including high specificity, low immunogenicity, minimal accumulation, and fewer drug-drug interactions, making them a novel and efficient therapeutic class for various diseases. In recent years, peptide-based drugs have shown great potential and broad application prospects in the treatment of oral infectious diseases, tissue injury and repair, tumors, and complex oral mucosal disorders, acting either through direct mechanisms or indirect modulation. Oral administration remains the preferred route due to its non-invasive, painless nature and ease of management; however, gastrointestinal pH can inactivate or even degrade peptide drugs.
View Article and Find Full Text PDFCrystal Facet-Engineered Anion Regulation Enables Fast-Charging Stability in Lithium Metal Batteries.
Angew Chem Int Ed Engl
September 2025
School of Chemistry, Engineering Research Center of Energy Storage Materials and Devices, Ministry of Education, National Innovation Platform (Center) for Industry-Education Integration of Energy Storage Technology, State Key Laboratory of Electrical Insulation and Power Equipment, Engineering Resea
Lithium metal batteries (LMBs) offer exceptional energy density and output voltage. However, their practical application remains hindered by sluggish ion transport and uncontrolled lithium dendrite formation, particularly under fast-charging conditions. Here, we report a facet-engineered anion-regulating separator based on zeolitic imidazolate framework-8 (ZIF-8) with preferentially crystal-exposed (110) facets.
View Article and Find Full Text PDFInterpretable Machine Learning for Proteomics-Based Subtyping and Tumor Mutational Burden Prediction in Endometrial Cancer.
Proteomics Clin Appl
September 2025
AIBioMed Research Group, Taipei Medical University, Taipei, Taiwan.
Background: Endometrial carcinoma (EC) represents a significant clinical challenge due to its pronounced molecular heterogeneity, directly influencing prognosis and therapeutic responses. Accurate classification of molecular subtypes (CNV-high, CNV-low, MSI-H, POLE) and precise tumor mutational burden (TMB) assessment is crucial for guiding personalized therapeutic interventions. Integrating proteomics data with advanced machine learning (ML) techniques offers a promising strategy for achieving precise, clinically actionable classification and biomarker discovery in EC.
View Article and Find Full Text PDFAdvances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.
Med Sci Monit
August 2025
Independent Laboratory of Translational Medicine, Medical University of Lublin, Lublin, Poland.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality, with high rates of recurrence and chemoresistance. Advances in understanding the molecular biology of EOC, particularly BRCA mutations and homologous recombination deficiency (HRD), have led to more targeted therapies. This review provides an updated summary of systemic treatments for EOC, with an emphasis on personalized therapy approaches and emerging therapeutic strategies.
View Article and Find Full Text PDF